Rapport Therapeutics, an organization whose neuroscience expertise comes from Johnson & Johnson, entered the general public markets on Friday, elevating $154 million for proof-of-concept testing of a lead program in improvement for a typical type of epilepsy. Rapport had introduced its plans to go public final month. Late Thursday, the biotech priced its providing of 8 million shares at $17 […]
